-
Product Insights
Bacteremia Disease - Global Clinical Trials Review, H2 2019
GlobalData's clinical trial report, “Bacteremia Global Clinical Trials Review, H2, 2019" provides an overview of Bacteremia clinical trials scenario. This report provides top line data relating to the clinical trials on Bacteremia . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Sector Analysis
HIV - First-In-Class Therapies Target Major Unmet Needs including Drug Resistance and Latency Reversal
Human immunodeficiency virus (HIV) is a chronic disease that can be transmitted through blood, semen, and other bodily fluids by means such as sexual contact, pregnancy and breastfeeding, the sharing of injection drug equipment, and blood transfusions. As the disease progresses, the virus causes depletion of a type of immune cell known as cluster of differentiation 4 (CD4) cells in the infected host. The loss of these cells leads to the progressive deterioration of the immune system, eventually resulting in...
-
Product Insights
Tinea Pedis (Athlete Foot) Disease - Global Clinical Trials Review, H1 2020
GlobalData's clinical trial report, “Tinea Pedis (Athlete Foot) Global Clinical Trials Review, H1, 2020" provides an overview of Tinea Pedis (Athlete Foot) Clinical trials scenario. This report provides top line data relating to the clinical trials on Tinea Pedis (Athlete Foot). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Helminthiasis (Parastici Worm Infestation) Disease - Global Clinical Trials Review, H1 2020
GlobalData's clinical trial report, “Helminthiasis (Parastici Worm Infestation) Global Clinical Trials Review, H1, 2020" provides an overview of Helminthiasis (Parastici Worm Infestation) Clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthiasis (Parastici Worm Infestation). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics – Global Drug Forecast and Market Analysis to 2024
Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths...
-
Sector Analysis
PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025
Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as...
-
Sector Analysis
PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026
Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories:...
-
Sector Analysis
Respiratory Syncytial Virus - Opportunity Analysis and Forecasts to 2028
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. The most common clinical scenario for RSV is an upper respiratory tract infection which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with...
-
Sector Analysis
Malaria: Opportunity Analysis and Forecasts to 2027
Malaria is a potentially life-threatening disease caused by Plasmodium parasites, which are transmitted to humans through the bites of infected female Anopheles spp mosquitoes. For over 2,500 years, fevers, a hallmark symptom of malaria, were attributed to miasmas (foul stenches or vapors) rising from nearby swamps. Scientific studies of malaria became possible only after Charles Louis Alphonse Laveran’s discovery of the causative parasite in 1880 and the subsequent incrimination of mosquitoes as the vectors—first for avian malaria by Ronald Ross...
-
Sector Analysis
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, in infants. RSV is also an...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.